Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
1.630
-0.050 (-2.98%)
May 13, 2026, 9:51 AM EDT - Market open
Traws Pharma Revenue
In the year 2025, Traws Pharma had annual revenue of $2.79M with 1,134.51% growth.
Revenue (ttm)
$2.79M
Revenue Growth
+1,134.51%
P/S Ratio
6.12
Revenue / Employee
$398,571
Employees
7
Market Cap
16.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.79M | 2.56M | 1,134.51% |
| Dec 31, 2024 | 226.00K | - | - |
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | 1.23M | 441.00K | 56.04% |
| Dec 31, 2017 | 787.00K | -4.76M | -85.81% |
| Dec 31, 2016 | 5.55M | -5.91M | -51.59% |
| Dec 31, 2015 | 11.46M | 10.66M | 1,332.00% |
| Dec 31, 2014 | 800.00K | -3.95M | -83.17% |
| Dec 31, 2013 | 4.75M | -41.44M | -89.71% |
| Dec 31, 2012 | 46.19M | 44.70M | 3,006.25% |
| Dec 31, 2011 | 1.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
| Exicure | 500.00K |
| Allarity Therapeutics | 320.00K |
| Outlook Therapeutics | 205.70K |
TRAW News
- 4 days ago - Traws Pharma files to sell 35.9M shares of common stock for holders - TheFly
- 4 days ago - There are no hantavirus treatments. The deadly cruise-ship outbreak is a ‘wake-up call' to develop some. - Market Watch
- 5 days ago - Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections - GlobeNewsWire
- 27 days ago - Traws Pharma Earnings Call Transcript: Q4 2025 - Transcripts
- 27 days ago - Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights - GlobeNewsWire
- 2 months ago - Traws Pharma completes clinical analysis of Phase 2 study of ratutrelvir - TheFly
- 2 months ago - Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewsWire
- 3 months ago - Traws Pharma initiated with a Buy at Ladenburg - TheFly